Taurochenodeoxycholic acid (TCDCA) has been identified as a potential biomarker for stratifying stages of hepatitis B virus-related hepatic cirrhosis, based on an analysis of 267 patients. This study found TCDCA to demonstrate anti-inflammatory and anti-fibrotic effects, distinguishing between chronic hepatitis B, compensated cirrhosis, and decompensated cirrhosis with notable sensitivity and specificity. Antiviral therapy was associated with lower TCDCA levels, linking viral suppression to bile acid balance. Researchers advocate for multicenter studies to further explore TCDCA's mechanisms and implications for liver fibrosis management.

Source: Scientific Reports